Atlas Trials

Study of PLK1 Inhibitor, Onvansertib, in Relapsed Small Cell Lung Cancer

Clinical trial NCT05450965 · RECRUITING

Trial details

NCT number
NCT05450965
Sponsor
University of Maryland, Baltimore
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Small-cell Lung CancerSmall Cell Lung Carcinoma
Start date
2022-07-19
Primary completion
2027-08-31
Enrollment
37

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.